Table 5.

Relation between HLA-E/β2m overexpression and objective response to cetuximab (p Fisher’s exact test).

	PR n = 15 (38%)	SD or PD n = 24 (62%)	Total n = 39	p value
METASTATIC TUMORS
HLA-E/β2m status
HLA-E−	10 (66.7%)	17 (70.8%)	27 (69.2%)
HLA-E+	5 (33.3%)	7 (29.2%)	12 (30.8%)	1.0
PRIMARY TUMORS
HLA-E/β2m status
HLA-E−	12 (80%)	19 (79.2%)	31 (79.5%)
HLA-E+	3 (20%)	5 (20.8%)	8 (20.5%)	1.0